ENX-101

• Description:

  ENX-101 is an orally active (GABAA) receptor partial positive allosteric modulator (PAM) . ENX-101 is selective to α2β2γ2L (EC50 = 0.76 nM), α2β3γ2L (EC50 = 0.61 nM), α3 (EC50 = 1.97 nM), α5 (EC50 = 0.85 nM) subunits of GABA receptor. ENX-101 possesses antiseizure activity in several animal models[1].

• UNSPSC:

  12352005

• Target:

  GABA Receptor

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Smiles:

  FC1=CC=C(F)C=C1C2=NN=C3N2N=C(OCC4=NC=NN4C)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=C3.O

• Molecular Formula:

  C19H12D9F2N7O2

• Molecular Weight:

  426.47

• References & Citations:

  [1]Serrats J, et al., ENX-101, a GABAA receptor α2,3,5-selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models. Epilepsia. 2025 Mar 15.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  Phase 2